FOR IMMEDIATE RELEASE

July 21, 2015

JCR Pharmaceuticals Co., Ltd. Eisai Co., Ltd.

JCR AND EISAI CONCLUDE FEASIBILITY STUDY AGREEMENT ON APPLICATION OF BLOOD-BRAINTO DISCOVER NEW TREATMENTS

JCR Pharmaceuticals Co., Ltd. (Headquarters: Ashiy

<Notes to editors>

1. About the Blood Brain Barrier (BBB)

In order to prevent various toxic substances from damaging brain tissue, it is essential to maintain stability in the brain through a function that limits the transfer of physical substances from the bloodstream to the brain. Consequently, it is necessary to allow energy sources for neural activity, such as amino acids and glucose, to pass through, while acting as a barrier to prevent most other substances from freely entering the brain. This barrier function is formed by tight junctions of endothelial cells that line the inside of brain capillaries (capillaries outside the brain adhere relatively loosely with endothelial cells, allowing various substances to pass through the tissue). While it is difficult for large molecules such as highly water-soluble substances and proteins to penetrate this barrier, nutrients and other essential materials are able to selectively pass the BBB by a system consisting of various receptors and transporters in the microvascular endothelial cells of the brain. Conversely, any unnecessary substance that enter the microvascular endothelial cells of the brain are prevented from invading the brain by transporters that will excrete these materials back into the bloodstream.

2. About JCR Pharmaceuticals

JCR is a specialty pharma engaged in the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, "Contributing towards people's healthcare through pharmaceutical products" drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient community.

3. About Eisai

Eisai is a leading